SCHEMBL14927458

SCHEMBL14927458

CCCn1c(=O)n(C(C)c2ccc(F)cc2)c(=O)c2cc(C)ccc21

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ RORA P35398 3/20 0.43
▸ RORC P51449 3/20 0.43
▸ RORB Q92753 3/20 0.43
▸ PGR P06401 2/20 0.43
▸ SLC6A2 P23975 1/20 0.42
▸ HPD P32754 1/20 0.40
▸ PLK1 P53350 1/20 0.39
▸ KDM4E B2RXH2 2/20 0.38
▸ ADORA2A P29274 2/20 0.38
▸ ADORA2B P29275 2/20 0.38
▸ TP53 P04637 1/20 0.37
▸ HRH1 P35367 1/20 0.36
▸ HTR6 P50406 1/20 0.36
▸ RXFP1 Q9HBX9 1/20 0.36
▸ POLB P06746 2/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ L3MBTL1 Q9Y468 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14927441 0.89 PGR (0.49) RORARORCRORBPGRSLC6A2
SCHEMBL10084495 0.84 KDM4E (0.44) KDM4ETP53POLB
SCHEMBL10085035 0.82 KDM4E (0.48) RORARORCRORBPGRKDM4E
SCHEMBL14927409 0.79 HRH1 (0.51) RORARORCRORBPGRPLK1
SCHEMBL10084697 0.78 PGR (0.57) RORARORCRORBPGRHPD
SCHEMBL14927482 0.76 ALDH1A1 (0.46) RORARORCRORBPGRPLK1
SCHEMBL14927467 0.75 RORA (0.40) RORARORCRORBPGRPLK1
SCHEMBL14927365 0.74 PGR (0.50) RORARORCRORBPGRADORA2A
SCHEMBL14927475 0.73 RORA (0.53) RORARORCRORBPGRHPD
SCHEMBL10085014 0.72 PARG (0.48) RORARORCRORBPGRSLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9732078-B2 Therapeutic use of imidazopyridine derivatives SANOFI (FR) 2017-08-15 — — US disclosed
US-9452164-B2 Imidazopyridine derivatives, process for preparation thereof and therapeutic use thereof SANOFI (FR) 2016-09-27 — — US disclosed
US-20140343054-A1 Therapeutic Use of Imidazopyridine Derivatives SANOFI (FR) 2014-11-20 — — US disclosed
US-20140243328-A1 IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2014-08-28 — — US disclosed
US-8759344-B2 Imidazopyridine derivatives, process for preparation thereof and therapeutic use thereof SANOFI (FR) 2014-06-24 — — US disclosed
US-20130116250-A1 IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-05-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140243328-A1 IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND THERAPEUTIC USE THEREOF CCNY, ENY2, PAH RORA 1071/4885RORC 1361/4885RORB 960/4885
US-20140343054-A1 Therapeutic Use of Imidazopyridine Derivatives CCNY, UTS2R, WNK2 RORA 2447/4885RORC 2557/4885RORB 2407/4885
US-20130116250-A1 IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND THERAPEUTIC USE THEREOF CCNY, ENY2, PAH RORA 1071/4885RORC 1361/4885RORB 960/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback